Friday, Feb. 22, 2019
- Time to Change Protocols for Post-SVR Monitoring for Liver Cancer?
- In Memoriam: Anita York (May 27, 1953 – Feb. 7, 2019)
- Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV)
- MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario
No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring Protocols?
Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV including HepCBC’s own Webmaster, CD Mazoff. Read more…
In Memoriam: Anita York
Our beautiful friend, Anita York (May 27, 1953 – Feb. 7, 2019), was honoured Feb. 17, 2019 in a private family ceremony. HepCBC, for whom she worked for many years as a key volunteer and as a Coordinator of Volunteers, is mourning the loss of this outspoken peer advocate, always ready to battle for anyone fighting hepatitis C, or to prevent even one more person from suffering from this debilitating disease. Read more…
Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV)
Funding of up to $2500 is available to support women’s self-directed health and education ideas…to improve health, wellness, skills building and social connectivity.” More Information at…
First deadline: March 15, 2019 (results announced March 30th).
MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario
Finally, Maviret, AbbVie’s hepatitis C drug, has made it through Canada’s approval process and has been listed for coverage by Ontario’s PharmaCare. We hope BC PharmaCare will also list it soon. “MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment.” Read more…